13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001643354
Total reported value
$20.9M
$20.9M
39 檔
26.0%
According to the latest 13F quarterly dataset, Lion Point Capital, LP managed an equity portfolio of $20.9M at the end of Q4 2025, spanning 39 distinct U.S. exchange-listed positions.
In Q4 2025, Lion Point Capital, LP displayed an active expansion posture, initiating 15 new positions and adding to 6 existing holdings, outstripping position reductions.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | MIST | Milestone Pharmaceuticals In | Stock-Other | 7.89% | -0.57% | +14.65% | |
| 2 | PRAX | Praxis Precision Medicines I | Stock-Other | 6.79% | -1.44% | -21.93% | |
| 3 | MLTX | Moonlake Immunotherapeutics | Stock-Other | 4.60% | -1.23% | — | |
| 4 | FENC | Fennec Pharmaceuticals Inc | Stock-Other | 4.48% | +1.65% | -8.59% | |
| 5 | JSPR | Jasper Therapeutics Inc | Stock-Other | 4.40% | -1.50% | +16.67% | |
| 6 | BNTC | Benitec Biopharma Inc | Stock-Other | 4.32% | +0.02% | — | |
| 7 | RPRX | Royalty Pharma plc | Stock-Healthcare | 4.28% | -0.40% | — | |
| 8 | GERN | Geron CORP | Stock-Other | 3.95% | -1.61% | +15.60% | |
| 9 | SNDX | Syndax Pharmaceuticals Inc | Stock-Other | 3.91% | -1.27% | -34.55% | |
| 10 | ARDX | Ardelyx Inc | Stock-Other | 3.88% | -1.47% | -20.95% | |
| 11 | CUE1EUR | Cue Biopharma Inc | Stock-Other | 3.48% | -3.03% | EXIT | |
| 12 | IRON | Disc Medicine Inc | Stock-Other | 3.33% | -0.27% | -23.58% | |
| 13 | SRPT | Sarepta Therapeutics Inc | Stock-Healthcare | 3.17% | -1.26% | — | |
| 14 | BHVN | Biohaven Ltd. | Stock-Other | 3.02% | +1.07% | +127.75% | |
| 15 | HUMA | Humacyte Inc | Stock-Other | 2.49% | +0.07% | +498.80% | |
| 16 | KURA | Kura Oncology Inc | Stock-Other | 2.47% | +0.17% | — | |
| 17 | MCRB | Seres Therapeutics Inc | Stock-Other | 2.43% | -0.48% | +16.33% | |
| 18 | CMPS | Compass Pathways PLC | Stock-Other | 2.07% | +2.77% | — | |
| 19 | DAWNGBX | Day One Biopharmaceuticals I | Stock-Other | 2.03% | — | — | |
| 20 | RGNX | Regenxbio Inc | Stock-Other | 1.98% | +0.19% | -53.94% | |
| 21 | BBIO | Bridgebio Pharma Inc | Stock-Healthcare | 1.98% | -0.44% | -62.41% | |
| 22 | MLYS | Mineralys Therapeutics Inc | Stock-Other | 1.97% | -0.34% | -73.08% | |
| 23 | VTYXUSD | Ventyx Biosciences Inc | Stock-Other | 1.94% | — | — | |
| 24 | LNTH | Lantheus Holdings Inc | Stock-Healthcare | 1.89% | +0.43% | — | |
| 25 | DYN | Dyne Therapeutics Inc | Stock-Other | 1.82% | -0.04% | — | |
| 26 | QURE | uniQure N.V. | Stock-Other | 1.82% | +1.80% | — | |
| 27 | PCRX | Pacira Biosciences Inc | Stock-Other | 1.81% | -0.18% | — | |
| 28 | VTRS | Viatris Inc | Stock-Healthcare | 1.78% | -0.14% | — | |
| 29 | AZTA | Azenta Inc | Stock-Other | 1.67% | -0.05% | — | |
| 30 | RCKT | Rocket Pharmaceuticals Inc | Stock-Other | 1.56% | -0.43% | — | |
| 31 | JANX | Janux Therapeutics Inc | Stock-Other | 1.36% | -0.18% | — | |
| 32 | EWTX | Edgewise Therapeutics Inc | Stock-Other | 1.17% | +0.06% | — | |
| 33 | INVA | Innoviva Inc | Stock-Other | 0.85% | -0.25% | — | |
| 34 | ARQT | Arcutis Biotherapeutics Inc | Stock-Other | 0.79% | -0.08% | -85.13% | |
| 35 | IPHA | Innate Pharma Sa-spons Adr | Stock-Other | 0.73% | +0.09% | — | |
| 36 | NERV | Minerva Neurosciences Inc | Stock-Other | 0.73% | — | — | |
| 37 | GHRS | GH Research PLC | Stock-Other | 0.67% | +0.45% | — | |
| 38 | SPRB | Spruce Biosciences Inc | Stock-Other | 0.45% | -0.13% | — | |
| 39 | MRSN | Mersana Therapeutics Inc | Stock-Other | 0.01% | — | -99.61% |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | PRAX | Praxis Precision Medicines I | +5.1% | -21.93% | Trim |
| 2 | MLTX | Moonlake Immunotherapeutics | +1.9% | — | Unchanged |
| 3 | HUMA | Humacyte Inc | +1.7% | +498.80% | Add |
| 4 | BHVN | Biohaven Ltd. | +1.1% | +127.75% | Add |
| 5 | MIST | Milestone Pharmaceuticals In | +0.4% | +14.65% | Add |
| 6 | SPRB | Spruce Biosciences Inc | +0.4% | — | Unchanged |
| 7 | DAWNGBX | Day One Biopharmaceuticals I | +0.4% | — | Unchanged |
| 8 | CMPS | Compass Pathways PLC | +0.2% | — | Unchanged |
| 9 | KURA | Kura Oncology Inc | +0.2% | — | Unchanged |
| 10 | GERN | Geron CORP | +0.1% | +15.60% | Add |
| 11 | RPRX | Royalty Pharma plc | 0% | — | Unchanged |
| 12 | RCKT | Rocket Pharmaceuticals Inc | 0% | — | Unchanged |
| 13 | MCRB | Seres Therapeutics Inc | -0.5% | +16.33% | Add |
| 14 | BNTC | Benitec Biopharma Inc | -0.6% | — | Unchanged |
| 15 | IRON | Disc Medicine Inc | -0.7% | -23.58% | Trim |
| 16 | SNDX | Syndax Pharmaceuticals Inc | -0.9% | -34.55% | Trim |
| 17 | JSPR | Jasper Therapeutics Inc | -1% | +16.67% | Add |
| 18 | MRSN | Mersana Therapeutics Inc | -1.1% | -99.61% | Trim |
| 19 | RGNX | Regenxbio Inc | -1.2% | -53.94% | Trim |
| 20 | ARDX | Ardelyx Inc | -1.2% | -20.95% | Trim |
| 21 | BBIO | Bridgebio Pharma Inc | -1.9% | -62.41% | Trim |
| 22 | FENC | Fennec Pharmaceuticals Inc | -2.1% | -8.59% | Trim |
| 23 | ARQT | Arcutis Biotherapeutics Inc | -3% | -85.13% | Trim |
| 24 | MLYS | Mineralys Therapeutics Inc | -6.4% | -73.08% | Trim |
| 25 | ✓ | Avadel Pharmaceuticals PLC ADR | — | EXIT | Sold out |
| 26 | KNSA | Kiniksa Pharmaceuticals International, plc | — | EXIT | Sold out |
| 27 | INSM | Insmed Inc | — | EXIT | Sold out |
| 28 | CUE1EUR | Cue Biopharma Inc | — | NEW | New buy |
| 29 | SRPT | Sarepta Therapeutics Inc | — | NEW | New buy |
| 30 | VTYXUSD | Ventyx Biosciences Inc | — | NEW | New buy |
| 31 | LNTH | Lantheus Holdings Inc | — | NEW | New buy |
| 32 | DYN | Dyne Therapeutics Inc | — | NEW | New buy |
| 33 | QURE | uniQure N.V. | — | NEW | New buy |
| 34 | PCRX | Pacira Biosciences Inc | — | NEW | New buy |
| 35 | VTRS | Viatris Inc | — | NEW | New buy |
| 36 | AZTA | Azenta Inc | — | NEW | New buy |
| 37 | JANX | Janux Therapeutics Inc | — | NEW | New buy |
| 38 | EWTX | Edgewise Therapeutics Inc | — | NEW | New buy |
| 39 | INVA | Innoviva Inc | — | NEW | New buy |
| 40 | IPHA | Innate Pharma Sa-spons Adr | — | NEW | New buy |
| 41 | NERV | Minerva Neurosciences Inc | — | NEW | New buy |
| 42 | GHRS | GH Research PLC | — | NEW | New buy |
According to official SEC Form 13F filings, Lion Point Capital, LP reported a total U.S. public equity portfolio value of $20.9M across 39 disclosed positions in Q4 2025.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including MIST, PRAX, MLTX) accounted for 26.0% of total reported equity market value during Q4 2025.
Top New Position Initiated
CUE1EUR
市值: $672.8K
Top Position Liquidated / Trimmed
Avadel Pharmaceuticals PLC ADR
前期市值: $911.6K
During Q4 2025, Lion Point Capital, LP's top holdings by market value included MIST (7.9%)、PRAX (6.8%)、MLTX (4.6%). The largest single position, MIST, represented 7.9% of total portfolio value.
In Q4 2025, Lion Point Capital, LP made 34 total portfolio adjustments, initiating 15 new buys, adding to 6 positions, trimming 10 holdings, and fully liquidating 3 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.